Quarterly ResultMay 14, 2026, 04:52 PM
Vivos Q1 Net Loss $(1.18M), Revenue $36K; Cash $2.53M
AI Summary
Vivos Inc. reported a net loss of $(1.18) million for Q1 2026, an increase from $(0.83) million in Q1 2025, primarily due to a $(651,628) loss on issuance of shares and warrant exchange. Despite this, the company saw a revenue increase to $36,068 from $26,748 year-over-year and significantly reduced operating expenses. The company's cash position improved to $2.53 million, bolstered by $1.55 million in financing activities, but it continues to face substantial doubt about its ability to continue as a going concern, requiring $3 million annually for operations.
Key Highlights
- Net loss increased to $(1,184,845) in Q1 2026 from $(834,696) in Q1 2025.
- Total revenues rose to $36,068 in Q1 2026 from $26,748 in Q1 2025.
- Operating expenses decreased significantly to $537,474 from $854,449 year-over-year.
- Cash balance increased to $2,525,782 as of March 31, 2026, from $1,558,525 at Dec 31, 2025.
- Raised $2,203,800 in March/April 2026 through equity and warrant sales.
- Net cash used in operating activities reduced to $(429,861) from $(455,198).
- Company requires $3 million annually and $9 million over 36 months for operations and trials.
- Established Vivos Scientific India LLP in October 2025 for manufacturing and human therapies.